Advair

Advair

(ăd′vâr′)
A trademark for drug combination of fluticasone propionate and salmeterol.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

Advair™

A proprietary inhalation product for treating asthma which combines salmeterol xinafoate—Serevent®, a long-acting bronchodilator—with fluticasone propionate—Flovent®, an inhaled corticosteroid anti-inflammatory—in a single breath-activated Diskus inhaler device.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
The strong performance helped to offset lower growth in its pharmaceuticals section after a rival firm got the green light to make a version of its profitable asthma drug Advair.
Glaxo's revenue boosted by new shingles vaccine
Emma Walmsley, CEO, GSK said: "GSK delivered continued good operating performance in Q2 despite the loss of exclusivity of Advair. We are increasing our expectations for the year and have updated our guidance for 2019.
GlaxoSmithKline reports Q2 adjusted EPS 30.5p, up 9% AER, up 4% CER
Wixela, a generic form of GlaxoSmithKlinePLC's Advair drug for chronic obstructive pulmonary disease, is expected to deliver "modest" revenue growth in the near-term.
Consort Medical Confident On Wixela Progress As Profit Declines
PITTSBURGH -- Mylan NV late last month won Food and Drug Administration approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first generic version of GlaxoSmithKline PLC's Advair Diskus.
Mylan Wins Approval for Wixela In hub
PHARMACEUTICAL giant Glaxo-SmithKline has posted rising sales but warned its profitability will take a hit due to competition against its asthma drug Advair.
Asthma drug competitor could impact Glaxo profits
The company added the Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP) is the first generic version of ADVAIR DISKUS.
Mylan wins US FDA approval for Wixela Inhub for treating asthma & COPD patients
The products that will no longer carry this boxed warning in their labels include AstraZeneca's budesonide/formoterol fumarate dihydrate (Symbicort) and GlaxoSmithKline's fluticasone furoate/vilanterol (Breo Ellipta) and fluticasone propionate/salmeterol (Advair Diskus and Advair HFA).
FDA axes LABA-steroid combo asthma drugs' boxed warning
Hikma is currently also in a dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the US.
Hikma wins right to market Roche drug copy in Middle East
* Advair (fluticasone propionate/salmeterol; GSK): Advair and Symbicort have similar NPS scores.
New Study: NPS+ Asthma/COPD (US)
Some big-selling products, like the respiratory medicine Advair and the diabetes drug Victoza, have suffered precipitous declines in market share because Express Scripts, the biggest pharmacy benefits manager, recently stopped paying for them for many patients.
Health plans tell drug makers: Cut costs or lose out; Bargain or be banned, insurers say
The respiratory franchise grew 6% to [pounds sterling]1.9 billion, with Advair sales of [pounds sterling]1.3 billion (+4%) and Flovent sales +7% to [pounds sterling]213 million.
GlaxoSmithKline

Medical browser ?
Full browser ?